{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:11:00Z","timestamp":1790799060953,"version":"4.1.0"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:sec id=\"ab-eoi250044-4\"><jats:title>Importance<\/jats:title><jats:p>Emerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs), commonly used for glycemic control in diabetes, may possess anti-inflammatory properties. Understanding their potential protective role against uveitis could provide insights into novel therapeutic strategies.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi250044-5\"><jats:title>Objective<\/jats:title><jats:p>To evaluate whether being prescribed a GLP-1RA is associated with a reduced risk of developing uveitis.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi250044-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This was a retrospective cohort study using electronic health record (EHR) network data from 2006 to 2025. Propensity score matching was applied to control for demographics, smoking status, hypertension, body mass index, hemoglobin A<jats:sub>1c<\/jats:sub>, and diabetic retinopathy stage. Data from the US Collaborative Network of TriNetX, a large multicenter EHR platform, were used in this analysis. Included were patients with and without diabetes with prescriptions for GLP-1RAs, metformin, insulin, or sodium-glucose cotransporter 2 inhibitors (SGLT2is). The control groups consisted of patients without prescriptions for each medication.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi250044-7\"><jats:title>Exposure<\/jats:title><jats:p>Use of GLP-1RAs, metformin, insulin, or SGLT2is, identified through prescription records.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi250044-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary outcome was the incidence of noninfectious uveitis, identified using <jats:italic>International Classification of Diseases <\/jats:italic>(<jats:italic>ICD<\/jats:italic>) encounter diagnosis codes. Risk ratios (RRs) with 95% CIs were calculated to assess the association between GLP-1RA use and uveitis risk. Analyses included risk of overall uveitis and subtypes such as chorioretinal inflammation, anterior uveitis, panuveitis, and retinal vasculitis.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi250044-9\"><jats:title>Results<\/jats:title><jats:p>A total of 516\u202f052 patients were included in this study, 258\u202f026 (mean [SD] age, 56.4 [13.7] years; 159\u202f025 female [61.6%]) in the GLP-1RA group and 258\u202f026 (mean [SD] age, 56.4 [14.0] years; 159\u202f374 female [61.8%]) in the control group. The GLP-1RA cohort had a reduced risk of uveitis compared with controls (RR, 0.48; 95% CI, 0.46-0.51). This was consistent among those with type 2 diabetes (RR, 0.54; 95% CI, 0.51-0.58) and those without diabetes (RR, 0.52; 95% CI, 0.46-0.59). Compared with the cohorts taking metformin (RR, 0.58; 95% CI, 0.54-0.62) and insulin (RR, 0.57; 95% CI, 0.54-0.61), GLP-1RA prescriptions were associated with greater protection against uveitis. However, GLP-1RAs were associated with a slightly increased uveitis risk vs SGLT2is (RR, 1.17; 95% CI, 1.04-1.32). SGLT2i prescriptions were also associated with reduced uveitis risk compared with controls (RR, 0.52; 95% CI, 0.48-0.56).<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi250044-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>This cohort study found that GLP-1RA prescriptions were associated with a lower risk of uveitis compared with controls. These findings suggest potential anti-inflammatory benefits beyond glycemic control, warranting further investigation into their role in ocular inflammatory diseases.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2025.2822","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T15:31:12Z","timestamp":1756395072000},"page":"823","source":"Crossref","is-referenced-by-count":13,"title":["Glucagon-Like Peptide-1 Receptor Agonists and Risk of Uveitis"],"prefix":"10.1001","volume":"143","author":[{"given":"Nitesh","family":"Mohan","sequence":"first","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio"},{"name":"Case Western Reserve University, Cleveland, Ohio"},{"name":"Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil K.","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio"},{"name":"Department of Ophthalmology, MetroHealth Hospital, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Schulgit","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio"},{"name":"Case Western Reserve University, Cleveland, Ohio"},{"name":"Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Nowacki","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio"},{"name":"Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Kaelber","sequence":"additional","affiliation":[{"name":"The Center for Clinical Informatics Research and Education, The MetroHealth System, Cleveland, Ohio"},{"name":"Department of Internal Medicine, Case Western Reserve University, Cleveland, Ohio"},{"name":"Department of Pediatrics, Case Western Reserve University, Cleveland, Ohio"},{"name":"Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Sharma","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio"},{"name":"Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"eoi250044r1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"eoi250044r2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multifaceted anti-inflammatory agent.","volume":"14","author":"Mehdi","year":"2023","journal-title":"Front Immunol"},{"issue":"7","key":"eoi250044r3","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.ophtha.2025.01.016","article-title":"Glucagon-like peptide-1 receptor agonist impact on chronic ocular disease including age-related macular degeneration.","volume":"132","author":"Allan","year":"2025","journal-title":"Ophthalmology"},{"issue":"9","key":"eoi250044r4","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.ophtha.2024.03.004","article-title":"Association between glucagon-like peptide-1 receptor agonists and the risk of glaucoma in individuals with type 2 diabetes.","volume":"131","author":"Niazi","year":"2024","journal-title":"Ophthalmology"},{"issue":"5","key":"eoi250044r5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ogla.2024.03.005","article-title":"Glucagon-like peptide 1 receptor agonists: a role in glaucoma?","volume":"7","author":"Johnson","year":"2024","journal-title":"Ophthalmol Glaucoma"},{"issue":"2","key":"eoi250044r6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1136\/bjophthalmol-2021-319232","article-title":"Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma.","volume":"107","author":"Sterling","year":"2023","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"eoi250044r7","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s00018-016-2147-8","article-title":"Inflammation and its role in age-related macular degeneration.","volume":"73","author":"Kauppinen","year":"2016","journal-title":"Cell Mol Life Sci"},{"issue":"15","key":"eoi250044r8","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.7150\/ijbs.49890","article-title":"The role of inflammation in age-related macular degeneration.","volume":"16","author":"Tan","year":"2020","journal-title":"Int J Biol Sci"},{"key":"eoi250044r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100916","article-title":"Inflammation in glaucoma: from the back to the front of the eye, and beyond.","volume":"83","author":"Baudouin","year":"2021","journal-title":"Prog Retin Eye Res"},{"issue":"12","key":"eoi250044r10","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.autrev.2017.10.010","article-title":"Uveitis: diagnostic work-up. a literature review and recommendations from an expert committee.","volume":"16","author":"S\u00e8ve","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"4","key":"eoi250044r11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3121\/cmr.4.4.294","article-title":"Cytokines and chemokines in uveitis: is there a correlation with clinical phenotype?","volume":"4","author":"Ooi","year":"2006","journal-title":"Clin Med Res"},{"key":"eoi250044r12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.740057","article-title":"TNF-a in uveitis: from bench to clinic.","volume":"12","author":"Jiang","year":"2021","journal-title":"Front Pharmacol"},{"issue":"3","key":"eoi250044r13","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1016\/S2665-9913(20)30008-4","article-title":"Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicenter, single-arm, phase 2 trial.","volume":"2","author":"Ramanan","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"eoi250044r14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/RHU.0000000000001949","article-title":"Glucagon-like peptide 1 receptor agonists in patients with inflammatory arthritis or psoriasis: a scoping review.","volume":"30","author":"Karacabeyli","year":"2024","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"eoi250044r15","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.3390\/ijms24021703","article-title":"GLP-1 receptor agonists in nonalcoholic fatty liver disease: current evidence and future perspectives.","volume":"24","author":"Nevola","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"4","key":"eoi250044r16","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae160","article-title":"GLP-1 analog use is associated with improved disease course in inflammatory bowel disease: a report from the Epi-IIRN.","volume":"19","author":"Gorelik","year":"2025","journal-title":"J Crohns Colitis"},{"issue":"2","key":"eoi250044r17","doi-asserted-by":"publisher","first-page":"543","DOI":"10.4049\/jimmunol.1502080","article-title":"Cutting edge: IL-1 receptor signaling is critical for the development of autoimmune uveitis.","volume":"196","author":"Wan","year":"2016","journal-title":"J Immunol"},{"issue":"1","key":"eoi250044r18","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/396204","article-title":"Proinflammatory cytokines and C-reactive protein in uveitis associated with Beh\u00e7et disease.","volume":"2014","author":"Mesquida","year":"2014","journal-title":"Mediators Inflamm"},{"issue":"1","key":"eoi250044r19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12348-019-0182-y","article-title":"Interleukin-6 inhibition in the management of non-infectious uveitis and beyond.","volume":"9","author":"Karkhur","year":"2019","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"10","key":"eoi250044r20","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis.","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"key":"eoi250044r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists.","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol Res"},{"key":"eoi250044r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2024.104885","article-title":"IL-10: a key regulator and potential therapeutic target in uveitis.","volume":"405-406","author":"Liu","year":"2024","journal-title":"Cell Immunol"},{"issue":"20","key":"eoi250044r23","doi-asserted-by":"publisher","first-page":"12428","DOI":"10.3390\/ijms232012428","article-title":"Anti-inflammatory effects of GLP-1R activation in the retina.","volume":"23","author":"Puddu","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"9","key":"eoi250044r24","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.autrev.2014.07.001","article-title":"Obesity in autoimmune diseases: not a passive bystander.","volume":"13","author":"Versini","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"12","key":"eoi250044r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111279","article-title":"Dietary caloric restriction protects experimental autoimmune uveitis by regulating Teff\/Treg balance.","volume":"27","author":"Li","year":"2024","journal-title":"iScience"},{"issue":"4","key":"eoi250044r26","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/JLB.MA0119-030RR","article-title":"Exacerbation of autoimmune uveitis by obesity occurs through the melanocortin 5 receptor.","volume":"106","author":"Muhammad","year":"2019","journal-title":"J Leukoc Biol"},{"issue":"1","key":"eoi250044r27","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3390\/ijms16010378","article-title":"Oxidative stress in obesity: a critical component in human diseases.","volume":"16","author":"Marseglia","year":"2014","journal-title":"Int J Mol Sci"},{"issue":"6","key":"eoi250044r28","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2174\/092986711794927694","article-title":"Emerging role of antioxidants in the protection of uveitis complications.","volume":"18","author":"Yadav","year":"2011","journal-title":"Curr Med Chem"},{"key":"eoi250044r29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.cytogfr.2018.10.002","article-title":"Pro-inflammatory cytokines: the link between obesity and osteoarthritis.","volume":"44","author":"Wang","year":"2018","journal-title":"Cytokine Growth Factor Rev"},{"issue":"6","key":"eoi250044r30","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jdiacomp.2018.03.008","article-title":"Glycemic control is an important modifiable risk factor for uveitis in patients with diabetes: a retrospective cohort study establishing clinical risk and ophthalmic disease burden.","volume":"32","author":"Ansari","year":"2018","journal-title":"J Diabetes Complications"},{"issue":"1","key":"eoi250044r31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12902-019-0421-0","article-title":"Determinants of poor glycemic control among adult patients with type 2 diabetes mellitus in Jimma University Medical Center, Jimma zone, south west Ethiopia: a case-control study.","volume":"19","author":"Mamo","year":"2019","journal-title":"BMC Endocr Disord"},{"issue":"2","key":"eoi250044r32","first-page":"32","article-title":"Characteristics associated with poor glycemic control among adults with self-reported diagnosed diabetes\u2014National Health and Nutrition Examination Survey, US, 2007-2010.","volume":"61","author":"Ali","year":"2012","journal-title":"MMWR Suppl"},{"issue":"2","key":"eoi250044r33","doi-asserted-by":"publisher","first-page":"402","DOI":"10.5114\/aoms\/174228","article-title":"The use of sodium-glucose cotransporter 2 inhibitors and the incidence of uveitis in type 2 diabetes: a population-based cohort study.","volume":"20","author":"Chung","year":"2024","journal-title":"Arch Med Sci"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2838119\/jamaophthalmology_mohan_2025_oi_250044_1759774132.10399.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T15:01:40Z","timestamp":1760626900000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2838119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2025.2822","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}